Repeated Low-Level Red-Light Intervention Prevents Myopia in Children
2023-04-26
临床结果
WEDNESDAY, April 26, 2023 -- A repeated low-level, red-light (RLRL) intervention is effective for preventing myopia among children with premyopia, according to a study published online April 26 in JAMA Network Open.
Xiangui He, Ph.D., from the Shanghai Eye Hospital, and colleagues conducted a 12-month school-based randomized clinical trial involving children in grades 1 to 4 with premyopia to examine the efficacy and safety of an RLRL intervention for preventing incident myopia. Children in the intervention group received RLRL therapy twice per day, five days per week, while those in the control group continued usual activities (139 children in each group).
The researchers found that the 12-month incidence of myopia was 40.8 and 61.3 percent in the intervention and control groups, respectively, representing a 33.4 percent reduction in incidence. Children in the intervention group who did not have treatment interruption secondary to the COVID-19 pandemic had an incidence of 28.1 percent, representing a 54.1 percent reduction in incidence. Significant reductions in myopic shifts in terms of axial length and cycloplegic spherical equivalence refraction were seen with the RLRL intervention (mean, 0.30 versus 0.47 mm; and −0.35 versus −0.76 D, respectively). On optical coherence tomography scans, there was no visual acuity or structural damage noted in the intervention group.
"Our findings have public health significance, especially for myopia prevention in countries with a high incidence of myopia," the authors write. "More studies are needed to understand the long-term efficacy and safety, optimal intervention dose, and potential underlying mechanisms of the RLRL intervention."
Two authors have a patent pending; one reported financial ties to Eyerising Ltd. and Eyerising International Pty Ltd.
Abstract/Full Text
Posted April 2023
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-药物
-热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。